Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

s evaluated using RECIST (Response Evaluation Criteria in Solid Tumors; an internationally recognized measure of disease progression) in patients with measureable disease showed an overall response rate of 8 percent (one partial response in 13 patients with measureable disease) and a 54 percent disease control rate (six of 13 patients with measureable disease). In comparison, published literature reports overall response rates of 8 to 12 percent in patients treated with docetaxel alone.
  • These data indicate that picoplatin can be safely administered with full-dose docetaxel. Neutropenia was the main hematologic toxicity. Thrombocytopenia was less severe and less frequent with picoplatin administered in combination with docetaxel compared with picoplatin administered alone.
  • These findings confirm and extend earlier Phase 2 results presented at the 20th European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland, in October 2008.

    "The encouraging PSA response rates, time to PSA progression and radiologic responses rates, combined with the promising safety results observed to date, support further development of picoplatin in combination with docetaxel and prednisone in advanced prostate cancer patients," said Robert De Jager, M.D., chief medical officer of Poniard. "We continue to collect and analyze data from this trial and expect to present updated clinical data, including time to disease progression and overall survival, at medical conferences later this year."

    About Picoplatin

    Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that it has an improved safety profile relative to existing platinum-based cancer therapies
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
    2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
    3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
    4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
    5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
    6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
    7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
    8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
    11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
    (Date:8/28/2014)... 28, 2014 Sterlitech is proud to ... to its stable of products . These ... cut-offs and include membrane filters with surface charges. ... customer demand for our membrane process testing equipment, and ... flat sheet membranes,” explains Sterlitech President Mark Spatz. ...
    (Date:8/28/2014)... BELLINGHAM, Washington, USA (PRWEB) August 27, 2014 ... Colorado next month for SPIE Laser Damage 2014 ... on optical materials for high-power lasers will run 14-17 ... international society for optics and photonics . , The ... key for understanding laser damage to optical materials will ...
    (Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
    Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
    ... SAN FRANCISCO, Calif., March 11 Raven,biotechnologies, inc., ... development of monoclonal antibody therapeutics (MAbs) for cancer,today ... RAV12 Phase,1/2a trial has been accepted as a ... the American Society of Clinical Oncology (ASCO).,The presentation ...
    ... in Western Pennsylvania Earn Designation, PITTSBURGH, March ... Allegheny General Hospital, UPMC Presbyterian Shadyside and UPMC,Passavant ... Cancers., Complex and rare cancers comprise approximately ... it difficult for patients to locate or,research facilities ...
    ... Ltd. has announced,development of a chemically synthesized vaccine ... its patented Replikins(TM) technology.,When the vaccine was administered ... lethal Taura virus. The specificity of the protective,effect ... the active,regions in the vaccine, and as a ...
    Cached Biology Technology:Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 2Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO 3Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2
    (Date:8/31/2014)... release is available in French . ... study just published in the prestigious Nature Neuroscience ... Research Centre of the Douglas Mental Health University Institute and ... neural circuitry and dynamic mechanisms controlling memory as well of ... a sub-region named the subiculum. , In 2009, they ...
    (Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
    (Date:8/29/2014)... of connections in transcription factor networks (TFNs) to evaluate ... published in PLOS Computational Biology in August. ... to a network,s resilience against mutations. , "In ... TFN models has a greater effect on robustness than ... said Dov A. Pechenick, PhD, lead author and former ...
    Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2
    ... 26, 2010) Consumption of 100 percent fruit juice ... diet quality in children and teens, according to new ... meeting. Two new studies from researchers at the ... Medicine clearly highlight the benefits of drinking 100 percent ...
    ... On April 15, 2010 , Dr. Stipkala joined a panel ... hosted by the University of South Carolina ,s NanoCenter in ... capitalists from all over the Southeast who are active in the nanotechnology ... Dr. Stipkala and ...
    ... YELLOWKNIFE, NT APRIL 2010 High in the Mackenzie ... tools being revealed as warming temperatures melt patches of ice ... Tom Andrews, an archaeologist with the Prince of Wales ... International Polar Year Ice Patch Study, is amazed at the ...
    Cached Biology News:Drinking 100 percent fruit juice is associated with improved diet quality in children 2Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel 2Ancient artifacts reveals as northern ice patches melt 2
    ... DEPC-treated Water is suitable ... is prepared by incubating with ... autoclaved to remove the DEPC.DNase/RNase-Free ... for use in all molecular ...
    Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
    The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
    Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: